TuisMNKD • NASDAQ
add
MannKind Corp
Vorige sluiting
$6,90
Dagwisseling
$6,82 - $7,01
Jaarwisseling
$3,17 - $7,62
Markkapitalisasie
1,89 mjd USD
Gemiddelde volume
2,53 m
P/V-verhouding
96,18
Dividend-opbrengs
-
Primêre beurs
NASDAQ
Finansieel
Inkomstestaat
Inkomste
Netto inkomste
| (USD) | Sep. 2024info | J/J-verandering |
|---|---|---|
Inkomste | 70,08 m | 36,73% |
Bedryfskoste | 36,84 m | 8,46% |
Netto inkomste | 11,55 m | 571,12% |
Netto winsgrens | 16,48 | 390,48% |
Wins per aandeel | 0,04 | 300,00% |
EBITDA | 17,33 m | 326,29% |
Effektiewe belastingkoers | 10,26% | — |
Balansstaat
Totale bates
Totale aanspreeklikheid
| (USD) | Sep. 2024info | J/J-verandering |
|---|---|---|
Kontant en korttermynbeleggings | 257,49 m | 72,33% |
Totale bates | 464,20 m | 44,91% |
Totale aanspreeklikheid | 674,13 m | 17,83% |
Totale ekwiteit | -209,93 m | — |
Uitstaande aandele | 275,78 m | — |
Prys om te bespreek | -9,08 | — |
Opbrengs op bates | 8,38% | — |
Opbrengs op kapitaal | 30,69% | — |
Kontantvloei
Netto kontantverandering
| (USD) | Sep. 2024info | J/J-verandering |
|---|---|---|
Netto inkomste | 11,55 m | 571,12% |
Kontant van bedrywe | 9,33 m | 7,70% |
Kontant van beleggings | -41,26 m | -257,23% |
Kontant van finansiering | -2,34 m | -727,56% |
Netto kontantverandering | -34,27 m | -981,66% |
Beskikbare kontantvloei | 5,19 m | 157,08% |
Meer oor
MannKind Corporation is a biopharmaceutical company focusing on the discovery, development, and commercialization of therapeutic products for diseases such as diabetes and pulmonary arterial hypertension. Based in Danbury, Connecticut, the company was founded in February 1991.
MannKind Corporation was named after its founder, Alfred E. Mann. Wikipedia
Gestig
Feb. 1991
Hoofkwartier
Webwerf
Werknemers
413
